BridgeBio Oncology Therapeutics (NASDAQ: BBOT) granted inducement stock options under its 2025 Inducement Plan on May 10, 2026. One new employee received options for 32,675 shares at an exercise price of $7.66 per share, vesting over four years, under Nasdaq Rule 5635(c)(4).
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – BBOT
-0.62%
1 alert
-0.62%News Effect
-$4MValuation Impact
$651.32MMarket Cap
0.1xRel. Volume
On the day this news was published, BBOT declined 0.62%, reflecting a mild negative market reaction.
This price movement removed approximately $4M from the company's valuation, bringing the market cap to $651.32M at that time.
Inducement options granted:32,675 sharesOption exercise price:$7.66 per sharePar value:$0.0001 per share+5 more
8 metrics
Inducement options granted32,675 sharesNon-qualified stock options under 2025 Inducement Plan to one new hire
Option exercise price$7.66 per shareExercise price equal to Nasdaq closing price on May 10, 2026
Par value$0.0001 per sharePar value of BBOT common stock underlying the inducement options
Initial vesting cliff25% after 1 yearOne-quarter of options vest on first anniversary of employee start date
Subsequent vesting schedule36 monthly installmentsRemaining options vest in 36 equal monthly installments thereafter
Grant dateMay 10, 2026Effective date of the inducement stock option grant
Plan adoption dateOctober 2025Board adoption month of the 2025 Inducement Plan
Number of hires1 employeeAwards made as a material inducement to a single March 2026 hire
Market Reality Check
Price:$8.54Vol:Volume 303,279 is 0.67x t...
low vol
$8.54Last Close
VolumeVolume 303,279 is 0.67x the 20-day average of 449,492, indicating subdued activity.low
TechnicalShares at $7.89 were trading below the 200-day MA of $10.83, and about 47% under the 52-week high of $14.87.
Peers on Argus
BBOT gained 3% while peers were mixed: AVXL +1.57%, IMNM +2.18%, IVA +3.2%, GERN...
BBOT gained 3% while peers were mixed: AVXL +1.57%, IMNM +2.18%, IVA +3.2%, GERN flat, PRAX -0.52%. No coordinated sector move evident.
Common CatalystSelect peers had their own catalysts (e.g., IMNM earnings, GERN clinical meeting news), pointing to stock-specific rather than sector-wide drivers.
Prior inducement stock option grant to a new hire under 2025 plan.
Pattern Detected
Recent BBOT news often produced modest moves, with positive clinical or regulatory updates generally met with small gains, but one notable selloff on otherwise positive preclinical data.
Recent Company History
Over the last month, BBOT has reported several RAS-pathway updates and corporate changes. On Apr 20, Fast Track designation for BBO-11818 saw shares rise 2.16%. AACR preclinical data for BBO-10203 on Apr 21 coincided with a -4.6% move, while additional AACR data on BBO-11818 the next day saw a 1.13% gain. Leadership changes and earlier inducement grants produced mixed but generally modest price reactions, framing today’s HR-related option grant within a pattern of frequent news flow.
Market Pulse Summary
This announcement details a routine inducement grant of 32,675 non-qualified stock options at $7.66 ...
Analysis
This announcement details a routine inducement grant of 32,675 non-qualified stock options at $7.66 per share to a recent hire, issued under BBOT’s 2025 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). In recent months, BBOT has combined HR and governance updates with significant pipeline progress and an FDA Fast Track designation. Investors tracking the story often focused on clinical milestones, evolving leadership, and the company’s ongoing use of equity-based compensation.
Key Terms
non-qualified stock options, par value, Nasdaq Listing Rule 5635(c)(4)
3 terms
non-qualified stock optionsfinancial
"The employee received non-qualified stock options to purchase 32,675 shares..."
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
par valuefinancial
"shares of BBOT common stock, par value $0.0001 per share, with an exercise price..."
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
Nasdaq Listing Rule 5635(c)(4)regulatory
"as a material inducement to the employees entering into employment... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.
The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $7.66 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.
All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).
About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
What inducement stock option grant did BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announce on May 12, 2026?
BridgeBio Oncology Therapeutics announced an inducement grant of non-qualified stock options to one new employee. According to BridgeBio Oncology Therapeutics, the options cover 32,675 BBOT shares, granted on May 10, 2026 under the company’s 2025 Inducement Plan.
How many BBOT shares are included in BridgeBio Oncology Therapeutics' May 10, 2026 inducement grant?
The inducement grant includes options to purchase 32,675 shares of BBOT common stock. According to BridgeBio Oncology Therapeutics, these non-qualified stock options were issued as a material inducement to employment for an individual hired in March 2026.
What is the exercise price and vesting schedule for BridgeBio Oncology Therapeutics' May 2026 inducement options (NASDAQ: BBOT)?
The options have a $7.66 exercise price and vest over four years. According to BridgeBio Oncology Therapeutics, 25% vests on the first anniversary of the start date, then monthly vesting in 36 equal installments, subject to continued service.
Why did BridgeBio Oncology Therapeutics grant BBOT inducement options outside stockholder-approved equity plans?
The company used its 2025 Inducement Plan to grant options as a hiring incentive. According to BridgeBio Oncology Therapeutics, the awards were issued outside stockholder-approved plans as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
How does Nasdaq Listing Rule 5635(c)(4) apply to BridgeBio Oncology Therapeutics' May 2026 BBOT option grant?
Nasdaq Listing Rule 5635(c)(4) allows equity awards as material employment inducements without shareholder approval. According to BridgeBio Oncology Therapeutics, the compensation committee approved these BBOT options as such an inducement for a new employee.
